Niclas mouse model of AML by targeting primitive LSK and progenitor cells BCL-2 inhibition with ABT-737 prolongs survival in an NRAS / BCL-2
暂无分享,去创建一个
D. Felsher | M. Konopleva | M. Andreeff | L. Sarda-Mantel | A. Whetton | P. Fenaux | M. Pla | A. Janin | C. Chomienne | N. Omidvar | A. Fan | C. Leboeuf | R. Padua | Stéphanie Beurlet | P. Gorombei | M. Noguera | P. Krief | A. W. Tu | R. West | Hervatin | P. Grange | Florence | C. L. Pogam
[1] P. Merlet,et al. Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes. , 2013, Leukemia research.
[2] L. Lam,et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.
[3] G. Dellino,et al. ABT-199: Taking Dead Aim at BCL-2 , 2013 .
[4] Hao Xiong,et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Konopleva,et al. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex , 2012, Leukemia.
[6] A. Roberts,et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. , 2011, Blood.
[7] C. François,et al. The Bcl-2 Homology Domain 3 (BH3) Mimetic ABT-737 Reveals the Dynamic Regulation of Bad, a Proapoptotic Protein of the Bcl-2 Family, by Bcl-xL , 2011, Molecular Pharmacology.
[8] C. Rudin,et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Hallek,et al. State of the art treatment of chronic lymphocytic leukaemia. , 2011, Blood reviews.
[10] S. Rai,et al. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression , 2010, Cancer biology & therapy.
[11] Gerard C Blobe,et al. Roles for the type III TGF-beta receptor in human cancer. , 2010, Cellular signalling.
[12] M. Minden,et al. Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. , 2010, Leukemia research.
[13] A. Roberts,et al. The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs , 2010, Molecular Pharmacology.
[14] D. Auboeuf,et al. Splicing factor and exon profiling across human tissues , 2010, Nucleic acids research.
[15] Yasodha Natkunam,et al. Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens , 2009, Nature Medicine.
[16] M. Butterworth,et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. , 2009, Blood.
[17] M. Fujita,et al. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. , 2009, The Journal of investigative dermatology.
[18] C. Scott,et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas , 2008, Proceedings of the National Academy of Sciences.
[19] B. Friguet,et al. Overexpression of Mitochondrial Methionine Sulfoxide Reductase B2 Protects Leukemia Cells from Oxidative Stress-induced Cell Death and Protein Damage* , 2008, Journal of Biological Chemistry.
[20] C. Tse,et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.
[21] D. L. Wilburn,et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. , 2008, Cancer research.
[22] M. Konopleva,et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway , 2008, Leukemia.
[23] I. Weissman,et al. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. , 2007, Cancer research.
[24] J. Cigudosa,et al. DNA profiling by arrayCGH in acute myeloid leukemia and myelodysplastic syndromes , 2007, Cytogenetic and Genome Research.
[25] G. Mufti,et al. Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? , 2007, Cancer research.
[26] C. Tse,et al. Bcl-2 family proteins are essential for platelet survival , 2007, Cell Death and Differentiation.
[27] P. Dent,et al. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. , 2007, Cancer research.
[28] John Calvin Reed,et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.
[29] C. Scott,et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.
[30] B. Williams,et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. , 2005, Blood.
[31] S. Flamant,et al. Osteopontin is upregulated by BCR-ABL. , 2005, Biochemical and biophysical research communications.
[32] Didier Auboeuf,et al. FAST DB: a website resource for the study of the expression regulation of human gene products , 2005, Nucleic acids research.
[33] T. Cotter,et al. Bcr‐Abl regulates osteopontin transcription via Ras, PI‐3K, aPKC, Raf‐1, and MEK , 2005, Journal of leukocyte biology.
[34] R. Craig,et al. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol , 2004, Oncogene.
[35] G. Mufti,et al. The Myelodysplastic Syndromes: A Matter of Life or Death , 2003, Acta Haematologica.
[36] Qiang Yu,et al. Bcl-2, via Its BH4 Domain, Blocks Apoptotic Signaling Mediated by Mitochondrial Ras* , 2003, The Journal of Biological Chemistry.
[37] J. Downing,et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. , 2002, Blood.
[38] H. Ackermann,et al. The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia , 2002, Leukemia.
[39] G. Mufti,et al. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. , 2000, Blood.
[40] A. Yen,et al. Regulation of MCL1 through a Serum Response Factor/Elk-1-mediated Mechanism Links Expression of a Viability-promoting Member of the BCL2 Family to the Induction of Hematopoietic Cell Differentiation* , 1999, The Journal of Biological Chemistry.
[41] H. Shapiro,et al. Accurate flow cytometric membrane potential measurement in bacteria using diethyloxacarbocyanine and a ratiometric technique. , 1999, Cytometry.
[42] Parker,et al. ‘Low‐risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro‐ versus anti‐apoptotic bcl‐2‐related proteins , 1998, British journal of haematology.
[43] I. Weissman,et al. The PEBP2betaMYH11 fusion created by Inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[44] S. Chevret,et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up , 1998, Leukemia.
[45] U. Maurer,et al. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[46] I. Weissman,et al. bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages , 1994, The Journal of experimental medicine.